Organism: Homo sapiens
Gene: 38659_at
Selected probe(set): 202777_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38659_at (202777_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.173419
Number of Samples:3 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):4.0154486
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-3.3172407
Number of Samples:2 / 4

Experimental	R547 study 1 (24h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

Relative Expression (log2-ratio):2.6401243
Number of Samples:3 / 3

Experimental	tunicamycin study 2 (2ug/ml; HCT 116)
	Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated HCT 116 cell sample
	Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-2.504262
Number of Samples:3 / 3

Experimental	echinomycin study 1
	Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control	deferoxamine study 5
	Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

Relative Expression (log2-ratio):-2.2711296
Number of Samples:3 / 4

Experimental	R547 study 4 (4h)
	Human colon carcinoma cell line HCT116 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 4 hours at a 3xIC90 concentration of 0.6 μmol/L. ATC code:---
Control	vehicle (DMSO) treated HCT116 cell sample
	Human colon carcinoma cell line HCT116 treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-2.1916428
Number of Samples:5 / 6

Experimental	colorectal adenoma study 2
	Laser microdissected human adenoma sample.
Control	normal colon tissue
	Laser microdissected human colonic epithelial cells sample.

Relative Expression (log2-ratio):2.14332
Number of Samples:2 / 2

Experimental	ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control	ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

Relative Expression (log2-ratio):2.0682364
Number of Samples:2 / 13

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	T-ALL study 2
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):1.9654026
Number of Samples:4 / 13

Experimental	precursor-B-ALL study 2 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	T-ALL study 2
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).